CytomX Therapeutics CTMX Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about CytomX Therapeutics's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CytomX Therapeutics's proceeds from exercises of stock options and other stock issuances?
- CytomX Therapeutics (CTMX) reported proceeds from exercises of stock options and other stock issuances of $281K in Q1 2026.
- What is the long-term trend for CytomX Therapeutics's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), CytomX Therapeutics's proceeds from exercises of stock options and other stock issuances has grown at a -24.5% compound annual growth rate (CAGR), from $2.5M to $811K.